Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes
Table 1
Demographic data, lens status, prior treatments, mean number of injections, mean duration between surgery and onset of PCME, and between the diagnosis of PCME and first DEX injection in all eyes, and with regard to the indication for surgery.
Parameter
All eyes
ERM
RRD
Mean age ± SD, years (range)
64.8 ± 10.2 (35–90)
66.2 ± 10.5 (35–90)
60.5 ± 8.0 (42–75)
Sex, n (%)
Male
27 (44.3)
19 (31.1)
8 (13.1)
Female
34 (55.7)
27 (44.3)
7 (11.5)
Laterality, n (%)
Right
30 (49)
23 (37.7)
7 (11.5)
Left
31 (51)
23 (37.7)
8 (13.1)
Lens status at surgery, n (%)
Phakic
27 (44.3)
24 (39.3)
3 (4.9)
Pseudophakic
34 (55.7)
22 (36.1)
12 (19.7)
Previous treatment, n (%)
43 (70.5)
31 (50.8)
12 (19.7)
Topical
11 (18)
9 (14.7)
2 (3.3)
Parabulbous triamcinolone
33 (54.1)
23 (37.7)
10 (16.4)
Naive
18 (29.5)
15 (24.6)
3 (4.9)
Mean number of injections, n ± SD
1.57 ± 0.7
1.67 ± 0.8
1.3 ± 0.6
1 injection, n (%)
35 (57.4)
23 (37.7)
12 (19.7)
2 injections, n (%)
17 (27.9)
15 (24.6)
2 (3.3)
3 injections, n (%)
9 (14.7)
8 (13.1)
1 (1.6)
Mean duration between surgery and onset of PCME (months)
3.4 ± 3.1 (0–12)
3.2 ± 3.2 (0–12)
4.1 ± 2.8 (1–12)
Mean duration between the diagnosis of PCME and first DEX (months)
